Analysts expect Central European Media Enterprises Ltd. (NASDAQ:CETV) to report $0.04 EPS on April, 26.They anticipate $0.35 EPS change or 112.90% from last quarter’s $-0.31 EPS. CETV’s profit would be $5.74M giving it 20.63 P/E if the $0.04 EPS is correct. After having $0.06 EPS previously, Central European Media Enterprises Ltd.’s analysts see -33.33% EPS growth. About 100,975 shares traded. Central European Media Enterprises Ltd. (NASDAQ:CETV) has risen 38.53% since September 12, 2016 and is uptrending. It has outperformed by 30.05% the S&P500.
Halozyme Therapeutics, Inc. is a biotechnology firm focused on developing and commercializing oncology therapies. The company has market cap of $1.68 billion. The Firm operates in research, development and commercialization of human enzymes and other drug candidates. It currently has negative earnings. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
About 226,869 shares traded. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 15.94% since September 12, 2016 and is uptrending. It has outperformed by 7.46% the S&P500.
Third Security Llc holds 10.28% of its portfolio in Halozyme Therapeutics, Inc. for 19.31 million shares. Senzar Asset Management Llc owns 1.23 million shares or 3.21% of their US portfolio. Moreover, Bb Biotech Ag has 2.78% invested in the company for 7.60 million shares. The California-based Snyder Capital Management L P has invested 1.29% in the stock. Iridian Asset Management Llc Ct, a Connecticut-based fund reported 10.74 million shares.
Ratings analysis reveals 83% of Halozyme Therapeutics’s analysts are positive. Out of 6 Wall Street analysts rating Halozyme Therapeutics, 5 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $12 while the high is $27. The stock’s average target of $16.50 is 26.05% above today’s ($13.09) share price. HALO was included in 9 notes of analysts from August 11, 2015. The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) has “Neutral” rating given on Friday, January 6 by Citigroup. Barclays Capital maintained the stock with “Overweight” rating in Wednesday, February 24 report. The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) has “Buy” rating given on Wednesday, November 18 by Citigroup. JMP Securities maintained it with “Market Outperform” rating and $20 target in Wednesday, March 9 report. The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) earned “Outperform” rating by Wells Fargo on Friday, December 4. Piper Jaffray maintained Halozyme Therapeutics, Inc. (NASDAQ:HALO) rating on Friday, September 16. Piper Jaffray has “Overweight” rating and $18 target. The firm has “Overweight” rating by Barclays Capital given on Tuesday, September 22. Deutsche Bank initiated the shares of HALO in report on Thursday, November 3 with “Buy” rating. The rating was maintained by JMP Securities on Tuesday, August 11 with “Market Outperform”.
Analysts await Halozyme Therapeutics, Inc. (NASDAQ:HALO) to report earnings on May, 8. They expect $-0.26 earnings per share, down 62.50% or $0.10 from last year’s $-0.16 per share. After $-0.21 actual earnings per share reported by Halozyme Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 23.81% negative EPS growth.
Central European Media Enterprises Ltd. is a media and entertainment firm operating in Central and Eastern Europe. The company has market cap of $473.39 million. The Company’s assets are held through a series of Dutch and Curacao holding companies. It currently has negative earnings. The Firm manages its business on a geographical basis, with six divisions: Bulgaria, Croatia, the Czech Republic, Romania, the Slovak Republic and Slovenia.
